Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
RAHWAY, N.J.--(BUSINESS WIRE) August 25, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)
Condition: Malaria Infection Interventions: Drug: M5717 60 mg; Drug: Pyronaridine; Drug: Atovaquone-Proguanil; Drug: M5717 200 mg; Drug: M5717 660mg Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
